CNN Money recently ran a Dow Jones Newswire story about Eli Lilly’s recent study using Cymbalta for reducing pain in fibromyalgia patients.*
Eli Lilly’s study claims that after one week fibromyalgia patients using Cymbalta had less pain than the control group taking a placebo. After three months, fibromyalgia patients receiving Cymbalta experienced significantly greater reduction in pain. The drug company has applied to the FDA for permission to market Cymbalta as a pain management drug for fibromyalgia.
Currently, the Federal Drug Administration (FDA) warns that a life-threatening condition called serotonin syndrome can happen when a medicine, like Cymbalta, is used with medicines used to treat migraine headaches.
In addition, the FDA has published a warning for children and adolescents with major depressive disorder (MDD), against using Cymbalta along with an antidepressant.
*NOTE: CNN Money appears to have pulled the article and it is no longer available online, so the link to the article has been removed.